ストックスクリーナーアプリを入手
1.965
5.35%
0.095
前日終値:
$1.87
開ける：
$1.96
24時間の取引高:
8.32M
Relative Volume:
0.63
時価総額：
$659.52M
収益：
$32.77M
当期純損益:
$-440.22M
株価収益率:
-1.1766
EPS:
-1.67
ネットキャッシュフロー:
$-400.48M
1週間 パフォーマンス:
+15.88%
1か月 パフォーマンス:
-12.05%
6か月 パフォーマンス:
-66.55%
1年 パフォーマンス:
-77.43%
1日の値動き範囲:
$1.945
$2.15
1週間の範囲:
$1.69
$2.15
52週間の値動き範囲:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
名前
Iovance Biotherapeutics Inc
セクター
電話
(650) 260-7120
住所
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
1.975 | 567.69M | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.39 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.37 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.94 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
565.28 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
253.25 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-16 | ダウングレード | UBS | Buy → Neutral |
| 2025-05-12 | ダウングレード | Truist | Buy → Hold |
| 2025-05-09 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-07-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-09-18 | 繰り返されました | Barclays | Overweight |
| 2023-05-30 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-08-18 | 再開されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Stifel | Hold → Buy |
| 2021-12-07 | 再開されました | Cowen | Outperform |
| 2021-06-10 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | ダウングレード | Stifel | Buy → Hold |
| 2021-05-03 | 開始されました | Truist | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2021-03-08 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 開始されました | Mizuho | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-04-29 | 開始されました | Piper Jaffray | Overweight |
| 2019-02-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-07 | 開始されました | Robert W. Baird | Outperform |
| 2018-12-31 | 再開されました | B. Riley FBR | Buy |
| 2018-07-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-04-10 | アップグレード | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 繰り返されました | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-01 | 繰り返されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Iovance Biotherapeutics Inc (IOVA) 最新ニュース
Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study - MarketScreener
Iovance Biotherapeutics Reports 61% Response Rate for Amtagvi® in Third-Line Melanoma Patients - Quiver Quantitative
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
IOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire
2025-07-13 | Investor Alert: Deadline Approaching to Join Iovance Biotherapeutics, Inc. (IOVA) Class ActionContact Levi & Korsinsky | NDAQ:IOVA | Press Release - Stockhouse
Iovance Biotherapeutics Sued for Securities Law ViolationsInvestors Should Contact Faruqi & Faruqi for More InformationIOVA - StreetInsider
IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm - GlobeNewswire Inc.
IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 14 Deadline in Securities Class Action – IOVA - TradingView
IOVA 2-DAY DEADLINE ALERT: Iovance’s (IOVA) CFO Resigns - GlobeNewswire
IOVA FRAUD ALERT: Iovance Biotherapeutics 44% Stock Drop - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - Morningstar
Investors who lost money on Iovance Biotherapeutics, Inc. - GlobeNewswire
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy - GlobeNewswire
Iovance Biotherapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. July 14, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire
IOVA DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, - GlobeNewswire
Shareholders that lost money on Iovance Biotherapeutics, - GlobeNewswire
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsELV - PR Newswire
IOVA SHAREHOLDERS: The Iovance Biotherapeutics July 14 - GlobeNewswire
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. - GlobeNewswire
Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesIOVA - FinancialContent
The Gross Law Firm Notifies Shareholders of Iovance Biotherapeutics, Inc. (IOVA) of a Class ... - Bluefield Daily Telegraph
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - FinancialContent
Wealth Enhancement Advisory Services LLC Lowers Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks And Legal PressureHagens Berman - ACCESS Newswire
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK - Bluefield Daily Telegraph
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER - GlobeNewswire
Iovance Biotherapeutics CFO Jean-Marc Bellemin to Depart - MarketScreener
ROSEN, A LEADING LAW FIRM, Encourages Iovance - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc.IOVA - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was - GlobeNewswire
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action - ACCESS Newswire
Shareholders that lost money on Iovance Biotherapeutics, Inc.(IOVA) should contact The Gross Law Firm about pending Class ActionIOVA - PR Newswire
Shareholders of Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights Before July 14, 2025 – Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance ... - Eagle-Tribune
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Urged to Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline - ACCESS Newswire
Iovance Biotherapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationIOVA - The Victoria Advocate
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA - TradingView
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - StreetInsider
Iovance Biotherapeutics Inc (IOVA) 財務データ
収益
当期純利益
現金流量
EPS
Iovance Biotherapeutics Inc (IOVA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
| Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
| Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
| Vogt Frederick G | Interim CEO & General Counsel |
May 14 '25 |
Buy |
1.69 |
25,000 |
42,250 |
374,646 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 14 '25 |
Option Exercise |
0.00 |
8,334 |
0 |
203,761 |
| Bellemin Jean-Marc | Chief Financial Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
58,590 |
0 |
87,938 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
62,106 |
0 |
120,880 |
0.05%
0.91%
大文字化:
|
ボリューム (24 時間):